des-moe-PRESS-in 
2 times per night to void (Nocdurna only)Absorption: <1% absorbed following oral or SL administration; nasal solution 10–20% absorbed; nasal spray 3–4% absorbed.
Distribution: Distribution not fully known. Enters breast milk.
Metabolism/Excretion: Primarily excreted in urine.
Half-life: PO — 1.5–2.5 hr; SL — 2.8 hr; IV — 75 min (↑ in renal impairment); Intranasal — 1.8–3.5 hr.
Contraindicated in:
Use Cautiously in:
CV: edema, hypertension, hypotension, tachycardia (large IV doses only).
Derm: flushing.
EENT: intranasal: epistaxis, nasal congestion, nasal discomfort, rhinitis, sneezing.
F and E: HYPONATREMIA, fluid retention.
GI: dry mouth, mild abdominal cramps, nausea.
GU: vulval pain.
Local: phlebitis at IV site.
MS: back pain.
Neuro: SEIZURES, dizziness, drowsiness, headache, listlessness.
Resp: dyspnea.
Drug-Drug:
Primary Nocturnal Enuresis
6 yr): 0.2 mg at bedtime; may be titrated up to 0.6 mg at bedtime to achieve desired response.Diabetes Insipidus
12 yr): DDAVP — 5–40 mcg (0.0.05–0.4 mL) in 1–3 divided doses.12 yr): 2–4 mcg/day in 2 divided doses.Hemophilia A/von Willebrand's Disease
Nocturia
IV Administration:
(PO, intranasal = antidiuretic effect; IV = effect on factor VIII activity)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | 1 hr | 4–7 hr | unknown |
| SL | unknown | unknown | unknown |
| Intranasal | 1 hr | 1–5 hr | 8–20 hr |
| IV | within min | 15–30 min | 3 hr† |
65 yrs and older and patients at ↑ risk of hyponatremia may require more frequent monitoring. May need to hold or discontinue therapy if hyponatremia occurs.NDC Code*